Alendronate is an effective way of increasing BMD and reducing bone turnover
The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosisJ Int Med Res. 2011;39(1):302-10
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
180 post-menopausal Chinese women, between 40 and 70 years of age, with osteopenia (T-score between -1.6 and -2.4), were randomized into 1 of 2 groups to study the effects of early antiresorptive drug intervention on osteopenia. The first group, classified as the treatment group, was given received 70 mg of alendronate once every 2 weeks plus 0.5 micrograms of alfacalcidol daily, while the second ...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE